Eloralintide clinical trials
Also written LY3841136.
How each study uses eloralintide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the eloralintide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2026 (16)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 16 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 26 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9
Studies that test eloralintide.
- Dec 2026A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightPhase 1 · Eli Lilly and Company
- Mar 2027A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesPhase 2 · Eli Lilly and Company
- Mar 2027A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.Phase 1 · Eli Lilly and Company
- Apr 2027A Study Assessing Eloralintide (LY3841136) in Healthy ParticipantsPhase 1 · Eli Lilly and Company
- Jun 2027A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 DiabetesPhase 1 · Eli Lilly and Company
- Jun 2027A Study of Eloralintide (LY3841136) in Female Participants With Obesity or OverweightPhase 1 · Eli Lilly and Company
- Aug 2027A Study of Eloralintide (LY3841136) in Participants With Overweight or ObesityPhase 1 · Eli Lilly and Company
- Sep 2027A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightPhase 2 · Eli Lilly and Company
- Sep 2027A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightPhase 2 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses eloralintide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 26
- A Study Assessing Eloralintide (LY3841136) in Healthy ParticipantsNot yet recruitingPhase 1Eli Lilly and CompanyNCT07935304Written as Eloralintide
- Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightRecruitingPhase 3Eli Lilly and CompanyNCT07353931Written as Eloralintide
- A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinRecruitingPhase 3Eli Lilly and CompanyNCT07392190Written as Eloralintide
- A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightRecruitingPhase 3Eli Lilly and CompanyNCT07369011Written as Eloralintide
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesRecruitingPhase 3Eli Lilly and CompanyNCT07282600Written as Eloralintide
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesRecruitingPhase 3Eli Lilly and CompanyNCT07881458Written as eloralintide and tirzepatide
- A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesNot yet recruitingPhase 3Eli Lilly and CompanyNCT07881432Written as eloralintide and tirzepatide
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskNot yet recruitingPhase 3Eli Lilly and CompanyNCT07900633Written as Eloralintide
- A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT07589608Written as Eloralintide
- A Study of Eloralintide (LY3841136) in Female Participants With Obesity or OverweightRecruitingPhase 1Eli Lilly and CompanyNCT07808060Written as Eloralintide
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT06143956Written as LY3841136
- A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesRecruitingPhase 3Eli Lilly and CompanyNCT07321886Written as Eloralintide
- A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightRecruitingPhase 1Eli Lilly and CompanyNCT07738614Written as Eloralintide
- A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 DiabetesNot yet recruitingPhase 1Eli Lilly and CompanyNCT07765511Written as Eloralintide
- A Study of Eloralintide (LY3841136) in Participants With Overweight or ObesityRecruitingPhase 1Eli Lilly and CompanyNCT07665879Written as Eloralintide
- A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.RecruitingPhase 1Eli Lilly and CompanyNCT07401862Written as LY3841136
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesActive, not recruitingPhase 2Eli Lilly and CompanyNCT07215559Written as Eloralintide
- A Study of Eloralintide (LY3841136) in Healthy ParticipantsActive, not recruitingPhase 1Eli Lilly and CompanyNCT07701083Written as Eloralintide
- A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesCompletedPhase 2Eli Lilly and CompanyNCT06603571Written as LY3841136
- A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionActive, not recruitingPhase 1Eli Lilly and CompanyNCT07426380Written as LY3841136
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesNov 4, 2026NCT07881458
Newly registered4
- A Study Assessing Eloralintide (LY3841136) in Healthy ParticipantsNov 13, 2026NCT07935304
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskOct 28, 2026NCT07900633
- A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesOct 19, 2026NCT07881432
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesOct 19, 2026NCT07881458
Codes
What other systems call eloralintide · ClinicalTrials.gg INT015388
- UNII (FDA) 73G3354J8WELORALINTIDEOne source FDA
- NCI Thesaurus C206906EloralintideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 73G3354J8W | ELORALINTIDE | One source FDA |
| NCI Thesaurus | C206906 | Eloralintide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.